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Abstract 
Apoptosis, programmed cell death, is a hot topic in recent research due to the 
potential applications to various areas by regulating its pathway.   In industrial large scale 
animal cell culture processes, research on how to regulate or predict the apoptotic 
pathway and understanding what signals the apoptotic cascade has lead to a new 
opportunity to enhance process robustness, improve final performance including 
productivity, and eventually, reduce production costs.  Current industrial cell culture 
processes normally involve a high cell density process in a large-scale bioreactor as a 
suspension culture that proliferates the cells beyond their optimal growth conditions.  
Under these conditions, apoptosis will be triggered, and consequently, cell viability will 
be decreased, and the chance for product degradation by the release of intracellular 
proteases and glycosidases will increase.  Therefore, characterizing which culture 
conditions will induce apoptosis during a particular cell culture process can be a valuable 
tool to optimize cell viability and possibly productivity.   Since the conventional method 
for cell count and viability measurement does not differentiate the cells in early to mid-
stage apoptosis from the normal cells, it would be difficult to understand the effect of 
early stage apoptosis.  This study elucidates the correlation between the culture 
conditions and apoptosis during a mammalian cell culture process and its effects on the 
productivity using real-time apoptotic assays for accurate cellular growth and death 
profiles.   Apoptosis induced by low pH, glucose and glutamine limitation, lactate 
toxicity and Camptothecin has been shown to significantly increase the yield and specific 
productivity most likely due to release of product during secondary necrosis at the 
culmination of the apoptosis pathway.
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1. Introduction 
1.1. Background 
Apoptosis is an important factor influencing viability, cell density, and 
productivity in a cell culture process.  Understanding how the rate of apoptosis is affected 
by the process conditions is useful to improve process performance and to develop a real-
time process monitoring methodology for troubleshooting purposes.  Cell death occurs by 
either necrosis or apoptosis.  Necrosis involves disruption of membrane integrity and is 
caused by severe physical or chemical damage to the cell.  The cell swells and bursts 
osmotically releasing its contents into the culture (Mazur et al., 1999).  On the other 
hand, apoptosis, or programmed cell death, is a sophisticated biochemical response to 
non-lethal stimuli, which allows for cell self-destruction of unwanted cells.  Figure 1 is a 
schematic diagram showing necrosis versus apoptosis in a cell.   
 
Figure 1. Necrosis versus Apoptosis 
Cell death occurs in two ways: necrosis or apoptosis.   Necrosis is caused by severe 
damage causing the cell to swell and burst.  Apoptosis occurs in response to non-lethal 
stimuli, which triggers a biochemical cascade resulting in characteristic morphological 
changes and self-destruction. (Figure from Cotter and Al-Rubeai, 1995) 
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The term “apoptosis” was first noted in 1972 in a paper by Kerr, Wyllie and 
Currie to define the highly regulated morphology and biochemistry of programmed cell 
death different from that of necrosis (Kerr et al., 1972).   The process of eliminating the 
DNA damaged, superfluous, or unwanted cells is characterized by nuclear chromatin 
condensation, cytoplasmic shrinking, and DNA fragmentation between nucleosomes into 
approximately 180 base pairs (Wyllie, 1980 reviewed by Hengartner, 2000).  Fairly early 
in the pathway, translocation of the phospholipid phosphatidylserine (PS) and 
intracellular proteins to the cell surface occurs.   This change is important since the 
exposure of the extracellular PS facilitates phagocytosis by macrophages in multicellular 
organisms (Fadok et al., 1992 reviewed by Hammill et al., 1999).  When the membrane 
phospholipid becomes externalized, endonucleases then destroy the cell’s DNA and the 
cytoskeleton is restructured before the cell body collapses into membrane-bound 
apoptotic bodies in a process called blebbing.  There is some indication in apoptotic B-
cell lymphoma that apoptosis in cells at the stage of PS externalization and chromatin 
condensation and cleavage can be reversed and that loss of membrane asymmetry 
precedes the commitment to cell death (Hammill et al., 1999; Vaughan et al, 2002; Simak 
et al., 2002).   
The complicated apoptosis process is controlled by a number of proteins 
including caspases (cysteine-containing aspartate-specific proteases) and can differ 
significantly based on the cell lines, culture conditions and stimuli (Al-Rubeai and Singh, 
1998; Fussenegger et al., 2000).  Under normal conditions, caspases are present as 
inactive proteins called procaspases or zymogens.  Once triggered by stress or damage, a 
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cascade of events occurs resulting in programmed cell death (Hengartner, 2000), (see 
Figure 2).   
 
Figure 2:  Apoptotic Cascade 
The apoptotic cascade is comprised of four main phases: initiation, signaling, effector, 
and degradation.  The pathway is initiated by a stimulus, which signals certain receptors 
on the cell surface.  These signals initiate the Bcl-2 family of survival factor proteins, 
releases mitochondrial proteins, and activate effector or executioner caspases.  The 
cascade ends with the degradation phase followed by either phagocytosis in vivo or 
secondary necrosis in vitro.   Throughout the pathway there are a number of ways the 
cascade is regulated including survival factors, caspase inhibitors and individual pathway 
blockers (noted on left).  (Figure from Mastrangelo and Betenbaugh, 1998) 
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There are two apoptotic pathways culminating in cell death:  the death receptor 
pathway and the mitochondrial pathway (Green, 2000), (see Figure 3).  Recent research 
has suggested a third pathway culminating in the endoplasmic reticulum causing the 
activation of caspase-12, however little is known at this time (Donovan and Cotter, 
2004).   
 
Figure 3: Apoptosis Pathway 
There are two main apoptotic pathways in the cell:  receptor mediated and mitochondrial.   
When a cell encounters an external stimulus, the receptor-mediated pathway is triggered 
causing a ligand to bind to a death receptor and the activation of an initiator caspase such 
as caspase 8.  The mitochondrial pathway is normally triggered by internal stresses up 
regulating certain Bcl-2 pro-apoptotic proteins (i.e. Bid), which causes mitochondria 
permeability and the release of apoptotic proteins such as Smac/DIABLO1, Apaf-1 and 
Cyt c.  Cyt c binds to Apaf-1, which then activates caspase 9.    Both caspase-8 and the 
apoptosome Caspase-9/Apaf-1 complex can trigger an executioner caspase such as 
caspase-3 leading to the amplification of executioner caspases and cell destruction.  IAP 
and Bcl-2 survival proteins are important for regulation of the process.  The Smac/Diablo 
complex is needed to inhibit the IAP family, which inactivates caspases.  (Figure from 
Laken and Leonard, 2001) 
 
                                                 
1 Abbreviations:  Smac/Diablo, second mitochondrial activator of caspases/direct inhibition of apoptosis 
protein binding protein with low pI; Apaf-1, apoptosis protein activating factor-1; Cyt c, cytochrome c; 
IAP, inhibitor of apoptosis proteins 
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The death receptor pathway is activated when the cell is exposed to an external 
stimulus, in most cases, that launches the cascade by activating the zymogen procaspase-
8 via the FAS/FADD death domain receptor.   Caspases are activated by cleavage after 
the C-terminal aspartic acid residue and in turn continue the cascade by cleaving other 
enzymes at their active site cysteine with a specificity determined by four residues on the 
N-terminal end of the cleavage site.  The procaspase-8/death receptor complex in turn 
activates the initiator caspases, caspase-2, 8, and 10, which triggers procaspase-3.  
Procaspase-3 with the help of caspase-8 and the apoptosome Caspase-9/Apaf-1 complex 
triggers the activation of caspase-3, an executioner or effector caspase.   
As the levels of executioner/effector caspases increase, the active caspase-8 also 
cleaves pro-apoptotic Bid, a Bcl-2 protein.  This in turn causes the mitochondria to 
release cytochrome c which complexes to APaf-1, a cytosolic protein, catalyzing 
procaspase-9 cleavage thereby producing initiator caspase-9.  An additional 
mitochondrial released protein, Smac/DIABLO, regulates the cascade by blocking the 
inhibitors of apoptosis protein (IAP) family, which bind to inactivate caspases.  The 
Smac/DIABLO regulation is necessary to promote caspase-9 activation (Laken and 
Leonard, 2001).  The pathways of the initiator caspases converge here to amplify 
additional executioner caspases (caspase-3, 6, 7).  The Bcl-2 family of survival factor 
proteins has pro-apoptotic and anti-apoptotic roles and it is these proteins that regulate 
the cytochrome c and apoptosis-inducing factor (AIF) release into the cytosol and 
additional caspase activation.  It is during this phase that apoptosis reversal is possible 
(Donovan and Cotter, 2004, Lukovic et al., 2003).  The relative ratio of death suppressor 
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and death inducer Bcl-2 proteins determines the fate of the cell (Korsmeyer, 1995 
reviewed by Al-Rubeai and Singh, 1998).   
The cascade of caspase receptor-mediated events ends with the degradation phase 
and the formation of apoptotic bodies followed by cell death either through phagocytosis 
in vivo or secondary necrosis in vitro (Mastrangelo and Betenbaugh, 1998).  The 
apoptotic pathway is regulated at various places in the cycle by different proteins.  For 
example, apoptosis triggered by DNA damage from irradiation or drugs used for cancer 
chemotherapy has been found to be dependant on p53, the tumor suppressor gene, which 
is the protein that senses DNA damage and halts replication (Kerr, 1995).  The p53 
protein is a key player in both growth arrest and apoptosis, forcing “bad” cells to commit 
suicide after DNA damage.  p53 has been shown to be a negative regulator of anti-
apoptotic Bcl-2 expression and is a key factor in cell cycle mediated apoptosis (Meikrantz 
and Schlegel, 1995; Fussenegger and Bailey, 1998).   
1.2. Importance and Applications of Apoptosis 
Interest in apoptosis research has increased considerably recently for a number of 
reasons including development of therapeutic treatments, cell culture technology 
development, metabolic engineering of mammalian cells and gene therapy.  Programmed 
cell death is important in a number of normal processes including metamorphosis of 
insects and amphibians, development of the human nervous system, the immune response 
and homeostasis in various organisms (Vaux, 1993; Lee et al., 2000).  Understanding the 
wide variety of stimuli that can induce or inhibit apoptosis is beneficial to research to 
develop therapeutic treatments to numerous diseases.  This includes cancer for failing to 
respond to apoptotic signals and Parkinson’s and Alzheimer’s diseases characterized by 
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excessive apoptotic activity of neurons (Thompson, 1995 and Haass, 1999 reviewed by 
Fussenegger et al., 2000).   
Apoptosis is detected almost exclusively in proliferating cells in cell culture 
processes and is particularly evident after periods of rapid cell growth (Fussenegger and 
Bailey, 1998; Meikrantz and Schlegel, 1995).  This phenomenon is the main cause of cell 
death in biopharmaceutical animal cell culture processes including those for baby 
hamster kidney (BHK), insect, Chinese hamster ovary (CHO), and mouse myeloma 
(NSO) cells; and therefore presents an opportunity for process optimization (Al-Rubeai 
and Singh, 1998).  The current industrial cell culture processes mostly involve a high cell 
density process in a large-scale bioreactor as a suspension culture that proliferates the 
cells beyond the optimal growth conditions.  Mild stimuli to the cells during a cell culture 
process caused by deprivation of nutrients (Singh et al., 1994), growth hormones and 
oxygen (Al-Rubeai and Singh, 1998) in the culture medium, sudden pH change, 
mechanical stress by agitation, or accumulation of cellular metabolites can cause 
apoptosis (Perreault and Lemieux, 1993; Arden et al., 2004).  During scale-up, there are 
many factors that contribute to cell damage and apoptosis, such as hydrodynamic shear 
and bubble damage caused by gas sparging (Marks, 2003).   In addition, the equipment 
design can have a significant effect on the presence of key nutrients, oxygen transfer, 
concentration of toxic metabolites, and shear stress.  There can also be issues with pH 
and dissolved oxygen (DO) gradients with inadequate mixing, all causing increased 
chance for apoptosis. 
Since the productivity of a protein of interest often depends on the final cell 
density and the specific productivity per cell, loss of actively growing and producing cells 
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by apoptosis during the production stage will cause a reduction of overall product yield.  
Mercille and Massie found that apoptosis accounts for the abrupt decrease in viability 
observed in late exponential phase of batch cultures (Mercille and Massie, 1994).  Dying 
cells release proteases and other components through secondary necrosis, which can 
lower the product yield through degradation and change in the product quality.  Thus, 
higher product consistency and quality can be achieved by employing well-defined and 
reproducible culture conditions and by minimizing the release of intracellular proteases 
and glycosidases.   
The most widely used methods for cell viability measurement using trypan blue 
dye or optical probes do not detect the cell population in the early stages of apoptosis.  
However, real-time monitoring of apoptotic events during a cell culture process could 
offer an opportunity to alter cell culture conditions much earlier to maintain cell viability 
and productivity or aid in process optimization during development stages (Vaughan et 
al, 2002).  When parameters such as temperature, dissolved oxygen, agitation, nutrient 
concentration, or pH levels fluctuate enough to trigger an apoptotic cascade during a cell 
culture process, the early detection of apoptotic events may allow for correction of the 
process conditions before irreversible damage has occurred to the culture (Hammill et al., 
1999).  It would also be beneficial to determine which conditions the cell culture is 
sensitive to and to add additional process control to minimize apoptosis levels during 
process characterization.   
Another application of apoptosis monitoring during a cell culture process is to 
prevent the cascade of events by using apoptosis-suppressing chemical additives, such as 
protease inhibitors and zinc ions, to block key effectors (Cohen and Al-Rubeai, 1995).  In 
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one such instance, suramin, a growth factor inhibitor and anti-tumor agent shown to 
inhibit apoptosis during the exponential growth phase, was added to a CHO cell culture 
process, which was observed to protect cells in serum-free culture where apoptosis is 
normally present due to nutrient limitation (Zhanghi et al., 2000).   Insulin and transferrin 
as well as caspase inhibitors are also now being investigated in this role.   In addition, 
antioxidants, such as Vitamin E, have been shown to prevent or at least delay apoptosis 
induced by free radicals; and aurintricarboxylic acid and N-acetylcysteine (Laken and 
Leonard, 2001) has been used to inhibit DNA cleavage, allowing for extended protein 
production in cells (Mastrangelo and Betenbaugh, 1998; Fussenegger and Bailey, 1998).   
It has also been shown that alleviating nutrient deprivation by feeding extra 
nutrients such as a single amino acid or glucose has rescued cultures from starvation-
induced apoptosis (Perreault and Lemieux, 1993; Franek and Sramkova, 1996).   In 
addition, an increase in metabolic byproduct levels such as lactate and ammonia from the 
catabolism of glucose and glutamine were found to decrease viability and specific 
productivity in BHK cells (Cruz, et al, 2000).  Optimization of nutrient additives to 
reduce glucose and glutamine and supplementation with three amino acids (glutamic 
acid, aspartic acid and cystine) has been shown to increase cell viability and enhance 
productivity in fed-batch CHO cultures by reducing the byproduct levels.  (Gorfien et al, 
2003).    
Furthermore, apoptosis induction is believed to be regulated by small changes in 
the intracellular environment such as pH since caspase activity is increased at acidic pH 
(Matsuyama et al., 2000 reviewed by Laken and Leonard, 2001).  In another instance, 
regulating hydrodynamic stress at the low level has been shown to suppress the apoptotic 
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process where high agitation rates have increased the apoptotic levels, which suggest 
these are areas for process characterization and optimization (Dimmeler et al., 1996 
reviewed by Al-Rubeai and Singh, 1998).  In addition, metabolic engineering using anti-
apoptotic survival genes has been reported to be effective in enhancing the survival 
properties under a wide variety of physiological stresses in bioreactors, such as nutrient 
and oxygen limitations, accumulation of toxic compounds and metabolites, and 
hydrodynamic stresses (Arden et al., 2004).   
Understanding the various stress-induced pathways involved in apoptosis can aid 
in cell engineering design to block stress signals and improve protein production 
(Fussenegger, 2001).  One example was based on c-jun antisense technology, which leads 
to proliferation control as well as enhanced resistance to apoptosis in Friend murine 
erythroleukemia (F-MEL) cells (Kim et al., 2000 reviewed by Laken and Leonard, 2001).  
Apoptosis has been shown to be cell-cycle specific in that most apoptosis occurs in 
transition from late stages of the G1 phase to the S phase of the cell cycle (Meikrantz and 
Schlegel, 1995).  Arrest prior to this phase delays or blocks apoptosis until the cell cycle 
continues (Fussenegger and Bailey, 1998).  Over expression of the bcl-2 and bcl-xL genes 
can inhibit the apoptosis cascade upstream protecting mammalian cells from stresses such 
as steroids, nutrient and serum deprivation, heat shock and irradiation (Vaux, 1993; 
Arden et al., 2004).  The gene blocks the release of cytochrome c from the mitochondria, 
decreasing the levels of procaspase-9 activation, which halts executioner caspase 
activation and therefore arrests apoptosis (Fussenegger et al., 2000).  In addition, cells 
that lack cytochrome c, Apaf-1 or caspase 9 are resistant stress-induced apoptosis 
(Reviewed by Green, 2000).  By decreasing the apoptotic levels in the culture, the 
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cellular lifetimes were extended during the stationary phase of growth leading to 
increased product yield (Mastrangelo and Betenbaugh, 1998). 
Because infinite proliferation beyond optimized cell density causes stress-induced 
apoptosis, a lot of recent research has focused on cell cycle-arrested cell technology.  
This technology has shown a significant increase in product productivity compared to the 
controls.  Multicistronic expression systems allow for a rapid nonproductive cell growth 
phase to the optimal density followed by a proliferation-arrested production phase in 
which cells devote all of their energy to the production of the desired protein and 
decrease the chances of nutrient depleted apoptosis.  One of the first examples was a 
temperature-sensitive CHO cell line in which lowering the temperature after the growth 
phase from 37°C to 30°C caused a growth arrest in the G1 phase and increased 
productivity by prolonging the production phase (Kaufmann et al., 1999; Moore et al., 
1997).   The decrease in temperature prolonged the cell viability by delaying apoptosis, 
not inhibiting the process.   The temperature shift caused a significant increase in the 
sialylation of the protein, which is a desirable effect in protein therapeutic uptake in vivo 
(Kaufmann et al., 2001).  However, the complex temperature regime was not attractive 
for industrial application and the temperature downshift altered protein expression 
causing posttranslational protein modifications.  Chemicals, such as sodium butyrate, 
have also been used to cause growth arrest and subsequent apoptosis regulation.  It has 
been used in conjunction with cells expressing bcl-2 to increase the production phase and 
decrease apoptosis (Simpson et al., 1997; Arden et al., 2004).   
Another example of the two phase metabolic engineering approach is the 
TETswitch proliferation-controlled production technology by Mazur and Fussenegger that 
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over expresses the cyclin-dependent kinase inhibitor gene, p27,  which results in G1 
phase cell-cycle-arrest in CHO cells (Mazur et al., 1998, 1999).  Induction of the 
proliferation-inhibited production phase from the non-productive growth phase occurs 
with the decrease in tetracycline in the culture.  This design allows for minimal levels of 
the antibiotic in the production medium, thereby avoiding complex and expensive 
downstream purification to clear it.  Tetracycline degrades over time so the system is 
self-regulated and predictable in the bioreactor conditions.  Productivity in these 
proliferation-inhibited cultures was as high as 10-15 times higher than normal cultures; 
and there were no significant changes to product quality (Kaufmann et al., 2001).  Meents 
and Fussenegger further engineered the process into a large-scale compatible non-
adherent serum-free process with increased production and decreased the use of animal 
serum, which is a current priority for regulatory agencies (Meents et al., 2002). 
There are many advantages to decreasing or understanding apoptosis in a cell 
culture process including a higher consistency of the product due to well-defined and 
reproducible conditions.  Another advantage would be a decrease in release of 
intracellular proteases and glycosidases so product quality is higher.  Optimizing the 
culture conditions could possibly lower medium consumption, decrease costs and 
increase productivity since intracellular resources can then be devoted to protein 
production.  Due to the highly redundant mechanisms in the apoptotic pathway, a mix of 
strategies for completely inhibiting apoptosis is most likely necessary including feeding 
schemes, chemical additives, metabolic engineering and survival gene expression (Arden 
and Betenbaugh, 2004).  The induction rates and overall effects of apoptosis are cell line 
dependent (Singh et al., 1994), and numerous studies have shown that the apoptotic 
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effects on protein production are dependent on a number of factors including the 
particular anti-apoptotic proteins expressed, cell type, expression system, and the culture 
environment.  Characterizing which conditions will have an influence on apoptosis in a 
particular cell culture process is valuable for enhancing robustness, optimizing cell 
viability and possibly increasing productivity.   
1.3. Problem Statement and Hypothesis 
Currently, most cell culture process conditions are developed based on optimizing 
cell density, viability and productivity without understanding the early stage apoptotic 
cell population.  Since conventional analytical methods do not detect early stage 
apoptotic levels, when lower cell viability is detected, it may be already too late to 
reverse the apoptosis cascade to sustain high productivity.  In order to understand the 
effect of the early stage apoptotic population on the final performance, a model 
mammalian cell line was evaluated for recombinant protein production during a cell 
culture process in bench scale bioreactors.   
Various experiments were performed to determine which process parameters 
increase programmed cell death and minimize viability.  The results were then evaluated 
to correlate the effects of apoptosis, the overall productivity of the cell culture process 
and the specific productivity per cell.  When these parameters such as temperature, 
dissolved oxygen, agitation, nutrient concentration or pH levels fluctuate enough to 
trigger an apoptotic cascade, this information could allow the stress-induced process to be 
reversed without detrimental effects in a manufacturing setting if detected early enough.  
Camptothecin (CPT) was used as a positive control to induce apoptosis by causing DNA 
damage (Lisby et al., 1998; Shimizu and Pommier, 1997).  CPT has been shown to 
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induce apoptosis in mammalian cells by inhibiting Topoisomerase I, which is an enzyme 
involved with DNA replication.   
Apoptotic phase, cell density, viability, and productivity were monitored 
throughout the process, as well as, pH, dissolved oxygen, carbon dioxide levels, and 
metabolite concentration.  A Guava® Technologies PCA-96 microcytometry system was 
used for apoptosis analysis.  The following assays were used as real-time process 
monitoring for this study: 
 Apoptosis: 
o ViaCount Assay: Cell density, viability determination, and apoptosis 
estimation 
o Nexin Method: Live, dead, early and late apoptotic cell discrimination 
o MultiCaspase Method: Viable, early to mid-apoptotic, late stage/dying 
and dead cells discrimination 
 Reversed-Phase HPLC:  Product titer 
 Blood Gas Analyzer: pH, carbon dioxide (CO2), and dissolved oxygen (DO) 
 Cedex: Automated Cell density and viability measurement based on trypan 
blue methodology 
 Nova BioAnalyzer: Metabolic concentration determination       
 
1.4. Viability and Apoptosis Assay Methodology 
 Initial studies showed the Guava Personal Cell Analysis (PCA) system to be a 
convenient method that may be beneficial to process development as a tool to quickly 
optimize a cell culture process under compressed timelines for improved cell viability 
and decreased apoptosis with minimal analyst-to-analyst variability compared to other 
methods.  Conventional methods of flow cytometry and microscopic analysis are 
expensive, time consuming and labor intensive which is unfavorable for modern 
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development and manufacturing cycles.   The Guava PCA allows for many assays to be 
run throughout the cell culture process to better understand how the conditions and stages 
of the process influence apoptosis.  The Guava assays allowed analysis of viable, 
apoptotic and dead cells as separate populations, whereas, trypan blue staining could only 
detect live and dead cell populations resulting in a more accurate lower viability for the 
ViaCount assay. 
1.4.1. ViaCount Assay 
The ViaCount assay determines the number of viable, mid/late apoptotic and dead 
cells in a sample based on uptake of two DNA-binding dyes with different cell 
permeability characteristics (Yokobata et al., 2003).  The assay is based on detecting cell 
membrane changes associated with apoptosis.  All cells take up the red dye in the 
ViaCount reagent so cellular debris is excluded.  Because of breached membrane 
integrity, later stage apoptotic and dead cells allow the orange dye from the reagent to 
absorb allowing for discrimination of the populations.  The conventional method for 
determining cell density and viability is trypan blue staining which can only detect live 
and dead cell populations.  Since apoptotic cells are unable to reproduce, the Guava 
technology was designed to not consider these cells viable, whereas the trypan blue 
method does not separate out the apoptotic from viable thereby giving an elevated viable 
cell number.    
1.4.2. Nexin Assay 
The Nexin assay is based on the biochemical and physiological characteristics of 
the apoptosis pathway (Guava Nexin Kit Insert, 2003; Fishwild and Tran, 2004).  An 
early characteristic of apoptosis is the translocation of the phospholipid 
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phosphatidylserine (PS) from the inner section of the plasma membrane to the cell 
surface as discussed earlier.  This serves as a signal for the cells to be cleared by 
phagocytes of the immune system in a normal physiological setting.  The Guava Nexin 
assay uses the dye Annexin V, which has a high affinity for PS to determine what 
percentages of cells in a population are undergoing early apoptosis.   
Secondly, the cell impermeable dye 7-amino actinomycin D (7-AAD) is used to 
distinguish between viable and dead cells based on membrane integrity.   It is excluded 
from healthy and early apoptotic cells, but is able to permeate later stage apoptotic and 
dead cells.  This assay detects earlier stage apoptosis in addition to late stage so a higher 
number of apoptotic cells are detected than in the ViaCount method.   
1.4.3. MultiCaspase Assay  
The activation of the caspase cascade in most cases commits a cell to death by 
apoptosis; therefore caspase enzymes (cysteine-containing aspartate-specific proteases) 
play a pivotal role in the initiation and execution of the apoptotic cascade (Guava 
MultiCaspase Detection Kit Insert, 2003).  The recognition of active caspase enzymes in 
a cell serves as a marker for mid and late stage apoptosis.  The Guava Multicaspase assay 
uses a cell permeable inhibitor called sulforhodamine-valyl-alanyl-aspartyl-
flouromethylketone (SR-VAD-FMK) to detect the cells that are expressing active 
caspases.  The SR-VAD-FMK dye binds covalently to multiple caspases in the cell that 
have been activated during apoptosis.  Similarly to the Nexin assay, this assay uses 7-
AAD to distinguish between viable and dead cells.     
1.4.4. Cedex Analyzer 
The Cedex AS20 (Innovatis AG; Bielefeld, Germany) is an automated analyzer of 
cell density and viability measurement based on the conventional trypan blue dye 
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methodology2.  The trypan blue method is the most currently used and widely accepted 
method for determining cell density and cell viability.  Trypan blue enters a cell once its 
outer plasma membrane integrity becomes compromised upon cell death.  This staining 
method distinguishes between viable cells, which exclude the dye due to intact outer 
membranes, and dead cells, which stain positive for trypan blue.  However, trypan blue is 
not able to discriminate between healthy, viable cells and cells that are undergoing 
apoptosis.  
2. Methods and Materials 
2.1. Cell Line and Culture Conditions 
An in-house recombinant mammalian cell line, growth medium and nutrient feed 
medium were used for all studies.  Bench scale and scale-up reactors were equipped with 
calibrated dissolved oxygen, pH and temperature probes.  Dissolved oxygen was 
controlled on-line through sparging with oxygen, and pH was controlled through 
additions of carbon dioxide or sodium bicarbonate.  The seeding density for all studies 
was kept constant.   
2.1.1. Study 1: Consistency Runs at Bench Scale and Scale-Up   
Study 1 consisted of five bench scale runs and one pilot scale run in which the DO 
and temperature were controlled at 120 mmHg and 37ºC, respectively.  The same batch 
medium and cells were used for both the bench scale and pilot scale runs to minimize 
process variation.  The pH set point was 7.0 at the start of the culture and then maintained 
at a pH of 6.8 once the culture pH dropped after 3 days incubation due to lactate 
accumulation in the broth.   Process samples were assayed daily for all six runs using the 
Blood Gas Analyzer, Cedex, and Nova Bioanalyzer for pH, carbon dioxide, DO, cell 
                                                 
2 http://www.innovatis.com/uk/produkte/cedex/cedex_glob.html 
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density, viability, and nutrient and metabolite concentrations (data not presented).  The 
ViaCount and Nexin apoptosis assays were run on Days 3, 6 and 9 for bench scale runs 
and 3, 6, 9 and 14 for the pilot scale run.  The multi-caspase apoptosis assay was run on 
Day 6 only for all six runs and product titer was performed on Days 3, 6, 8, 10, 12 and 
14.  These runs were mainly used to determine assay conditions and gating specific for 
the cell type as described in the analytical section to follow.    
2.1.2. Study 2: Base Concentration and pCO2 Addition Runs 
Study 2 consisted of eighteen-bench scale runs designed to mimic the pH and 
carbon dioxide profiles in the pilot scale process.  At the start of the culture, the process 
was designed with the pH set at 7.0.  pH decreased over time as the cells released carbon 
dioxide.  Once the pH reached 6.8, it was maintained at the set point of 6.8 with base and 
carbon dioxide addition, which was added to the culture broth through a sparger.  
Because the carbon dioxide stripping was more efficient in the bench scale runs, the pH 
did not drop at the same rate as the scaled-up process (Marks, 2003).  A new bench scale 
process was designed to more closely mimic the scaled-up process.  The pH was 
programmed to drop to 6.8 during the first several days of the process at a rate of -0.007 
pH units/hr and was used on all runs.  The sparged carbon dioxide was added as a fixed 
percentage of the oxygen sparge rate from 0 to 20%.   
In addition, the concentration of the base solution (0.1 – 0.5 M sodium 
bicarbonate) for pH control was varied to determine if unusually high osmolality was 
caused by overshoot between base and acid (in this case CO2) addition during pH control 
in the bench scale runs.  Lower base concentrations were tested to determine a more 
accurate addition to mimic that in the scaled-up process.  The culture conditions for 
Study 2 are summarized in Table 1.  All of the runs were assayed daily using the Blood 
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Gas Analyzer, Cedex, and Nova Bioanalyzer.  The ViaCount and Nexin apoptosis assays 
and product titer were run on Days 3, 6, 8 10, 12 and 14.  The MultiCaspase apoptosis 
assay was run on Days 6, 8, 12 and 14.   
Table 1: Test Conditions for Study 2 
 
 
Run # CO2 Flow Rate (% of O2 Flow Rate) 
Base Concentration 
(M) 
1 0 0.5 
2 0 0.5 
3 0 0.5 
4 0 0.5 
5 0 0.5 
6 0 0.5 
7 10 0.25 
8 10 0.25 
9 10 0.25 
10 10 0.25 
11 10 0.1 
12 10 0.1 
13 10 0.1 
14 10 0.1 
15 20 0.25 
16 20 0.25 
17 20 0.1 
18 20 0.1 
2.1.3. Study 3: Nutrient Starvation and Apoptosis Induction 
Runs 1 through 3 from Study 2 were continued past Day 14 for Study 3 to 
increase the levels of apoptosis during the extended incubation in the reactors.  The test 
conditions are summarized in Table 2.  Reactor 1 was the control; and the nutrient feed 
was ended for Reactor 2 on Day 14.  Reactor 3 was induced with a known apoptosis 
inducer, (S)-(+)-Camptothecin (CPT, Sigma-Aldrich Cat# C9911), to a final 
concentration of 5 mM.  The CPT was dissolved in dimethyl sulfoxide (DMSO, 
Mallincrokrodt) and added to the reactor through a 0.2µm syringe filter on Day 14.  The 
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reactors were sampled daily on the Blood Gas Analyzer, Cedex, Nova Bioanalyzer, 
ViaCount, Nexin, and MultiCaspase apoptosis assays and product titer.   
Table 2: Test Conditions for Study 3 
Run # Additional Conditions Days 14-17 
1 Control 
2 Nutrient Starvation 
3 Apoptosis Induction w/ 5 mM Camptothecin 
2.1.4. Study 4: pH and DO Characterization Runs and Camptothecin 
Controlled Apoptosis Induction 
Study 4 varied the pH and DO levels individually at five set points.  Runs 9 and 
10 were the control runs with conditions at pH 6.8 and 120 mmHg.  The study conditions 
are summarized in Table 3.  The pH was programmed to begin decreasing at a process 
time of 72 hours at a rate of -0.007 pH units/hr until the pH dropped to the test pH stated 
in Table 3.  For the pH 6.9 and 7.0 conditions, the pH ramp was not implemented.  The 
carbon dioxide was sparged at a flow rate of 10% of the oxygen sparge rate starting on 
Day 4 of the process in order to match the scale up process profile determined in Study 2.  
The base concentration used in the bench scale runs was 0.1 M sodium bicarbonate, 
which was shown to prevent increased osmolality from Study 2 (data not shown).  In 
addition to the eighteen pH/DO reactors, Runs 19 and 20 were performed with the pH 
and DO center points and induced on Day 8 with CPT dissolved in DMSO through a 0.2 
µm syringe filter to a final concentration of 1 µm.  On Day 3 of the process, the reactor 
agitator malfunctioned in Run 20 resulting in no mixing for approximately 3 hours. 
All of the runs were assayed daily using the Blood Gas Analyzer, Cedex, and 
Nova Bioanalyzer.  The ViaCount assay was run on Days 3, 6, 8, 9, 10, 12 and 13, 
whereas the Nexin and MultiCaspase apoptosis assays were run on Days 8, 9, 10, 12 and 
Page 26 of 71 
13.  The product titer was run on Days 3, 6, 8, 10, 12 and 14 (Day 13 for Runs 19 and 
20).   
Table 3: Test Conditions for Study 4
DO pH setpoint Run # 
(mmHg) (pH units) 
1 60 6.8 
2 60 6.8 
3 100 6.8 
4 100 6.8 
5 140 6.8 
6 140 6.8 
7 180 6.8 
8 180 6.8 
9 120 6.8 
10 120 6.8 
11 120 6.6 
12 120 6.6 
13 120 6.7 
14 120 6.7 
15 120 6.9 
16 120 6.9 
17 120 7.0 
18 120 7.0 
19* 120 6.8 
20*+ 120 6.8 
∆ pH 
∆ DO 
Controls 
 
*Reactor induced with 1 µM Camptothecin on Day 8 
+Reactor agitator malfunctioned on Day 3 resulting in no mixing for approximately 3 hours. 
 
2.2. Guava Assays 
The following assays used the Guava Technologies PCA-96 system (Guava 
Technologies; Hayward, CA) (Guava Technologies, 2004; Mukwena et al., 2003)3.   
                                                 
3 The Guava assay methods were originally developed by Lindsey Holt and Todd Lumen, Internal 
Technical Report, Amgen Thousand Oaks, Cellular Process Development, December 2004 
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2.2.1. Guava ViaCount Assay 
2.2.1.1.  Procedure 
Cells were stained with the ViaCount reagent (Guava Technologies, Cat# 4000-
0040) depending on the cell concentration within 5 hours of sampling.  Cell 
concentrations from 1x105 to 1x106 cells/ml were diluted 1:10 in staining solution (50 µl 
of cell solution and 450 µl of ViaCount reagent), cell concentrations from 1x106 to 1x107 
cells/ml were diluted 1:20 in staining solution (20 µl of cell solution and 380 µl of 
ViaCount reagent), and cell concentrations over 1x107 cells/ml were diluted 1:40 in 
staining solution (10 µl of cell solution and 390 µl of ViaCount reagent).  The samples 
were then incubated at room temperature for 5-15 minutes before data acquisition on the 
Guava PCA-96 system (1000 cells counted/sample in triplicate).  The system was 
calibrated daily using the recommended Guava Check application. 
 The Consistency Runs during Study 1 were used to set the intensity gates for the 
ViaCount assay for the cell line and assay conditions.  The gates allow for discrimination 
between viable, mid-apoptotic and dead cells reproducibly.  The gate details are 
summarized in Table 4 and Figure 4 shows a typical ViaCount dot plot with the gated 
lines for a Day 6 and Day 17 samples.  The gates were set to position the live population 
in the upper left corner of the dot plot.   
Table 4: ViaCount Gates 
Viability Discriminator Apoptosis Discriminator 
X Intercept Line Angle X Intercept Line Angle 
0.21 30.3 0.91 29.6 
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 Fig. 4A: Day 6 Fig. 4B: Day 17 
Viable Cells 
↓ ← Dead Cells 
↔   Mid- Apoptotic Cells 
Figure 4:  ViaCount Assay Dot Plot Examples 
Cells were assayed using the Guava ViaCount method at different time points throughout 
the culture, shown here are Days 6 (A) and 17 (B).  The gates were set during the control 
runs for this cell line to position the viable (live) cells at the upper, left corner of the dot 
plot.  The different stages determined by the method are labeled in Figure A.  There is an 
increased number of mid-apoptotic and dead cells in the Day 17 sample.  
 
2.2.2. Guava Nexin Assay 
2.2.2.1.Procedure 
The cell samples were diluted with Phosphate Buffered Saline (PBS, Gibco; 
Grand Island, NY) to concentrations between 2x105 and 1x106 cell/ml in a total volume 
of 50 µl within 5 hours of sampling.  The cells were spun in a microcentrifuge for 3 
minutes at 500xg, after which 45 µl of the supernatant was removed and discarded.  Each 
cell pellet was resuspended in a working solution consisting of 150 µl 1X Nexin Buffer 
(prepared from 10X Nexin Buffer, Guava Technologies, Cat# 4200-0060), 5 µl Annexin 
V-PE (Guava Technologies, Cat# 4700-0040), and 5µl Nexin 7-AAD (Guava 
Technologies, Cat# 4000-0060).  The cells were incubated on ice for 20 minutes, shielded 
from light.  After incubation, the total sample volume was brought to 350 µl by adding 
185 µl of 1X Nexin Buffer before acquisition on the Guava PCA-96 system (2000 cells 
counted/sample, flow rate setting medium).  The Nexin intensity gates were set to 
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position the live population in the lower left corner of the dot plot.  The angles of the 
gates were then positioned to divide the dot plot into four quadrants.  Each quadrant of 
the dot plot contains a distinct population of cells that is dependent on the presences and 
intensity of cellular stains per cell.  The Nexin intensity gates needed to be adjusted 
slightly from assay to assay due to the nature of the assay and to properly discriminate the 
four populations under analysis.  Examples of the Nexin Dot Plot are shown in Figure 5. 
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 Fig. 5A: Day 14 
Cell  
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Viable 
Cells →
 
 
Fig. 5B: Day 17 
Figure 5: Nexin Assay Dot Plot Examples 
Cells were assayed using the Guava Nexin method at different time points throughout the 
culture, shown here are Days 14 (A) and 17 (B).  The gates are set to position the viable 
(live) cells at the lower, left corner of the dot plot.  The quadrants are labeled in Figure A 
to show the different stages the Nexin method identifies.  There is an increased number of 
Late Stage/Dead Cells (upper right) in the Day 17 sample.  
 
2.2.3. Guava MultiCaspase Assay 
2.2.3.1.Procedure 
Prior to staining, 5x104 cells from each sample were brought to a total volume of 
100 µl with 1X Apoptosis Wash Buffer (prepared from 10X Apoptosis Wash Buffer, 
Guava Technologies, Cat# 4200-0162) within 4 hours of sampling.  To each sample, 5 µl 
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of 20X SR-VAD-FMK (prepared from SR-VAD-FMK reagent, Guava Technologies, 
Cat# 4100-0212) was added.  The samples were incubated in a 37ºC/5% CO2 incubator 
for 1 hour, shielded from light, and were mixed once by gently vortexing during that 
period.  Following incubation, the cells were washed three times with 1 ml of 1X 
Apoptosis Wash Buffer and centrifuged at 300 to 400xg in a microcentrifuge for 5 
minutes to pellet the cells. The samples were then resuspended in 100 µl of 1X Apoptosis 
Wash Buffer and each stained with 5 µL of Caspase 7-ADD (Guava Technologies, Cat# 
4000-0064) for 10 minutes at room temperature, shielded from light.   
Before acquisition on the Guava PCA-96 system, 200 µl of 1X Apoptosis Wash 
buffer was added to bring the sample volume to 305 µl.  Data was acquired within 15 
minutes after adding the 7-AAD dye.   The MultiCaspase intensity gates were set each 
assay run and were not consistent from assay to assay due to the nature of the assay 
similar to that in the Nexin assay.  Examples of the MultiCaspase Dot Plot are shown in 
Figure 6. 
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 Fig. 6A: Day 14 
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Fig. 6B: Day 17 
Figure 6: MultiCaspase Assay Dot Plot Examples 
Cells were assayed using the Guava MultiCaspase method at different time points 
throughout the culture, shown here are Days 14 (A) and 17 (B).  The gates are set to 
position the viable (live) cells at the lower, left corner of the dot plot (teal green).  The 
quadrants are labeled in Figure A to show the different stages the MultiCaspase method 
identifies.  There is an increased number of Late Stage/Dying Cells (pink) in the Day 17 
sample.  
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2.3. Other Analytical Methods 
2.3.1. Cedex Analyzer 
2.3.1.1.Procedure 
A daily sample from the bioreactor was mixed gently and 1000 µl of the sample 
was added to a Cedex AS20 cup and analyzed per manufacturer’s recommended method. 
Samples were diluted 1:2 in PBS for Days 8 through 17.   
2.3.2. Blood Gas Analyzer 
2.3.2.1.Procedure 
The Chiron CIBA-Corning 248 Blood Gas Analyzer (Chiron Diagnostics; 
Halstead, Essex, UK) was used to measure real time pH, carbon dioxide, and oxygen 
levels4.  The values are used to calibrate the bioreactor controllers on a daily basis as 
needed.  A daily sample from the bioreactor was removed with a 3 ml syringe and 
immediately analyzed on the Blood Gas Analyzer following the manufacturer’s 
recommended method.   
2.3.3. Nova BioAnalyzer 
2.3.3.1.Procedure 
The Nova Biomedical BioProfile 100 Plus (Nova; Waltham, MA) was used to 
monitor the progress of the bioreactor runs by determining the consumption and 
production of key metabolites, growth limiting nutrients and waste products5.  The Nova 
analyzes pH, glutamate, lactate, glutamine, glucose, sodium, potassium, ammonium, and 
osmolality.  A daily sample from the bioreactor was removed with a 3 ml syringe and 
analyzed on the Nova BioAnalyzer following the manufacturer’s recommended method.   
                                                 
4 http://www.gmi-inc.com/Categories/bloodgas.htm 
5 http://www.novabiomedical.com/bioprofile/bpanalyzers.html 
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2.3.4. Reversed-Phase HPLC 
2.3.4.1.Procedure 
The concentration of recombinant protein was determined by applying samples to 
a reversed-phase column on a High Performance Liquid Chromatography (HPLC) 
system.  Bioreactor samples were centrifuged for 5 minutes at 2000 rpm and supernatant 
was removed and frozen at -30ºC until all samples from the study were taken and then 
assayed by an Agilent 1100 HPLC system.  The titer samples were run by the Analytical 
Sciences group in Process Development. 
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3. Results & Discussion 
3.1. Conventional Trypan Blue versus Guava Method for Determining Viability 
Since the rate of apoptosis and the stimuli signaling the pathway can vary from 
cell line to cell line, this study looked at a model mammalian cell line to determine the 
effects certain conditions have on cell viability.  Figure 7 shows Runs 1 through 3 from 
study 3 in which the reactors were extended to 17 days.  The Figure shows the viable cell 
density and viability for each run as measured from the conventional trypan blue method 
compared to the Guava ViaCount method.   
As seen in Figure 7, for the first 8 days of the culture when viability was high the 
two methods readings were very similar.  In all three runs, a small dip in the ViaCount 
viable cell density is seen around Days 8 through 10 at which time the two methods start 
to show different results indicating apoptosis is occurring in the cultures. The viable cell 
density for all 3 runs started to decrease on Day 14.  Run 3 viable cell density dropped 
significantly after the addition of CPT on Day 14 due to the excessively high 
concentration of CPT added.  The concentration most likely caused necrosis in some cells 
in addition to apoptosis over time.  Nutrient starvation was used in Run 2 to try and 
induce apoptosis; the viable cell density decreased steadily until Day 16, however the 
viability remained high compared to the other two reactors.   
On Day 16, additional nutrients were added to Run 2 to keep the viability high to 
determine the affects of different levels of apoptosis on the productivity (to be discussed 
later).  At this time, the viable cell density remained stable, but the viability started to 
decline steadily based on the ViaCount method.  By the end of Day 17, the two viability 
methods showed significantly different results; the trypan blue method indicated a 27% 
higher viability than the ViaCount result for Run 1 and 18% and 17% for Runs 2 and 3, 
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respectively.  Based on this data, the ViaCount method appears to provide more 
representative results of the actual viability in the process when apoptosis is present in the 
culture. 
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Run 3:  CPT Induction
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Figure 7: Viable Cell Density and Variability over Time with Apoptosis Induction 
Growth curves of cells from Study 3 with apoptosis induction at Day 14 by nutrient 
starvation (Run 2) and CPT induction (Run 3).  The culture was continued through Day 
17.  The viable cell density (solid line) and viability (dotted line) for the conventional 
trypan blue method using the Cedex instrument (blue) are compared to the Guava 
ViaCount method (pink) for the three runs.  The two methods are similar through Day 8 
of the process when viability was high and start to differ with increased apoptotic levels 
during later stages.  The end viability at Day 17 is noted on the right with notable 
differences between the two assays due to apoptosis levels, which are not detected in the 
conventional trypan blue method. 
  
In addition to the ViaCount method, two other apoptosis assays were used to 
determine various stages of the apoptosis process in the culture.  Table 5 summarizes the 
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different levels of viability using these two methods in addition to the ViaCount and 
trypan blue methods for Day 17 of Runs 1 through 3.  The Nexin assay shows the 
percentage of cells in early stages of apoptosis whereas the MultiCaspase assay provides 
data for the early/mid and late/dying stages of the culture.   
Table 5: Summary of Day 17 Cell Viability using Different Analytical Methods 
 
Distribution of Cell Population (%)  
 
Cell 
Viability 
Method 
Run # 
Live 
(Non-Apoptotic) 
Early 
Apoptosis 
Mid 
Apoptosis 
Late 
Apoptosis Dead 
1 52.4 4.2 37.2 6.2 
2 66.1 4.6 22.3 7.0 MultiCaspase 
3 40.2 3.3 50.2 6.3 
1 35.5 2.5 56.4 (5.7% Nuclear Debris) 
2 54.0 3.0 38.8 (4.2% Nuclear Debris) Nexin 
3 30.7 3.2 64.0 (2.2% Nuclear Debris) 
1 52.5 18.6 28.9 
2 69.4 12.2 18.4 ViaCount 
3 37.9 10.8 51.3 
1 79.8 21.2 
2 87.5 12.5 
 
Trypan Blue 
 3 54.6 46.4 
 
3.2. Effects on Productivity with Increased Run Time, CPT Apoptosis Induction, 
and Nutrient Feed Starvation 
The three runs were analyzed for protein titer to determine the affect apoptosis 
had on the productivity.  Although the viability and viable cell density was highest in the 
nutrient feed starved culture in Run 2, the overall recovery was lowest among the three 
runs, (see Table 6).  Run 1 and Run 3 had an 11% and 30% increase in productivity 
respectively compared to Run 2.  Run 3, with the lowest viability and viable cell density, 
had the highest productivity.  Furthermore, the specific productivity was highest in Runs 
1 and 3 with the increased apoptotic levels and lowest viability.   Figure 8 shows the 
effects of specific productivity over time for the three runs.  This most likely occurred at 
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the culmination of the apoptosis cascade resulting in product being released when 
secondary necrosis transpired.  
Table 6: Total Protein Yield after Various Levels of Apoptosis Induction 
Run # 
Normalized  
Total Protein  
(mg) 
1: Control 1966 
2: Nutrient Starvation 1772 
3: CPT Induction 2304 
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Figure 8: Effects on Specific Productivity with Various Levels of Apoptosis 
This figure shows the specific productivity over time for the three runs in Study 3.  The 
specific productivity was similar through Day 14 when the conditions changed to vary 
the apoptotic levels in the cultures.  Run 3 with the lowest viability and viable cell 
density, had the highest specific productivity by Day 17 followed closely by Run 1 which 
also had high apoptotic levels.   
 
3.3. pH, DO Levels, Apoptosis Induction Earlier in Process, and Agitation Issues 
DO and pH levels were characterized in Study 4.  Figures 9 and 10 show the 
viable cell density and viability over the duration of the culture for the varying DO levels.  
A shift in the viable cell density was found in all 18 runs of this study on Day 9 and 
increased again by Day 10.  A small shift in viability was also seen suggesting stimulus 
was introduced during this time.  Based on statistical analysis discussed later, this is most 
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likely due to nutrient deprivation in the higher cell densities in the culture.  The total and 
specific productivity for these runs are summarized in Figure 11.  The DO levels had 
minimal effect on the specific productivity of the cells; however the specific productivity 
was highest in the 180 mmHg, which had the lowest viable cell density.  Figure 12 shows 
the total and viable cell count and normalized total protein of each DO condition over the 
duration of the process.  The viable cell density and total protein yield are highest in the 
lower DO conditions.   This is consistent with literature findings that showed that low DO 
levels in reactors prolong cell viability thereby increasing the productivity (Reuveny et 
al., 1986).   
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Figure 9: Viable Cell Density Profiles at Various DO Levels 
Viable cell density profiles of cells cultured at various dissolved oxygen levels from 
Study 4.  The viable cell density was determined by the Guava ViaCount method 
throughout the 14-day culture.   
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Figure 10: Cell Viability Profiles at Various DO Levels 
Cell viability (% live) profiles of cells cultured at various DO levels from Study 4.  The 
viability was determined by the Guava ViaCount method throughout the 14-day culture.   
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Figure 11: Total Protein Yield and Specific Productivity for Varying DO Levels 
Figure 11 shows the effects of different DO levels in the culture on productivity (blue) 
and specific productivity (red) at the end of the 14-day cultivation.  The specific 
productivity was highest in the 180 mmHg, which had the lowest viable cell density.  
Productivity decreases as the DO levels increase. 
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Control: pH 6.8, DO 120 mmHg, no CPT
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Figure 12: Viable Cell Density and Total Productivity as a Function of Time at 
Various DO Set Points 
Growth profiles of cells cultured with various DO set points from Study 4 for the 14-day 
culture period.  The total cell density (pink) and the viable cell density (yellow) were 
measured by the Guava ViaCount assay.  The normalized total protein is noted in aqua.   
 
Page 42 of 71 
Figures 13 and 14 show the viable cell density and viability over the duration of 
the culture for the varying pH levels.  The specific productivity for these runs is 
summarized in Figure 15.  Interestingly, the pH 6.6 condition had a high specific 
productivity result and increased levels of apoptosis in the culture indicating that 
secondary necrosis may have occurred.   This is consistent with literature findings that 
apoptosis induction is believed to be regulated by small changes in the intracellular 
environment such as pH since caspase activity is increased at acidic pH (Matsuyama et 
al., 2000 reviewed by Laken and Leonard, 2001).  Figure 16 shows the total and viable 
cell count and normalized total protein of each pH condition over the duration of the 
process.  The pH level had a significant effect on the viable cell density, however the 
viability was not too different between the 5 runs with the exception of the pH 6.6 
condition which had a significantly lower viability earlier in the process compared to the 
other runs.   
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Figure 13: Viable Cell Density Profiles at Various pH Levels 
Viable cell density profiles of cells cultured at various pH levels from Study 4.  The 
viable cell density was determined by the Guava ViaCount method throughout the 14 day 
culture.   
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Figure 14: Cell Viability Profiles at Various pH Levels 
Cell viability (% live) profiles of cells cultured at various pH levels from Study 4.  The 
viability was determined by the Guava ViaCount method throughout the 14-day culture.   
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Figure 15: Total Protein Yield and Specific Productivity at Various pH Levels 
Figure 15 shows the effects of different pH levels in the culture on productivity (blue) 
and specific productivity (red) at the end of the 14-day cultivation.  
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Control: pH 6.8, DO 120 mmHg, no CPT
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Figure 16: Viable Cell Density and Total Productivity as a Function of Time at 
Various pH Set Points 
Growth profiles of cells cultured with various pH set points from Study 4 over the 14-day 
culture period.  The total cell density (pink) and the viable cell density (yellow) were 
measured by the Guava ViaCount assay.  The normalized total protein is noted in aqua.   
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Figures 17 and 18 show the viable cell density and viability over the duration of 
the culture with CPT induction on Day 8.  The CPT induction had a significant effect on 
the viable cell density and viability in the two runs.  The normalized total protein yield 
and specific productivity for these runs are summarized in Figure 19.  Although the 
viable cell density was significantly lower in the CPT induced cultures, the yield was still 
similar to the control; therefore the specific productivity was significantly greater in these 
runs. 
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Figure 17: Viable Cell Density with CPT Induction 
Viable cell density profiles of cells induced with CPT on Day 8 from Study 4.  The viable 
cell density was determined by the Guava ViaCount method throughout the 14-day 
culture.   
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Figure 18: Cell Viability with CPT Induction 
Cell viability (% live) profiles of cells induced with CPT on Day 8 Study 4.  The viability 
was determined by the Guava ViaCount method throughout the 14-day culture.  Run 20 
started out with a lower viability due to the agitator malfunction on Day 3 and remained 
slightly lower throughout the cultivation.   
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Figure 19: Total Protein Yield and Specific Productivity with CPT Induction 
Figure 19 shows the effects of CPT induction in the culture on productivity (blue) and 
specific productivity (red) at the end of the 14-day cultivation. Final productivity was not 
affected. 
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3.4. Statistical Analysis 
All of the data from the runs in Study 2 and 4 were statistically analyzed using 
JMP Software.  The most significant factors affecting overall viable cell density for Study 
4 were the addition of the CPT to the reactors and dissolved oxygen levels, (see 
Appendix 1).  When both studies were included and the CPT parameter was removed, the 
most significant factor affecting the live cell numbers was pH.  Next, the ViaCount 
viability response was analyzed and the most considerable effects came from CPT 
induction and decreased glucose levels in the culture, (see Appendix 2).  Glucose can be 
a limiting substrate during abnormally elevated rates of glycolysis, such as in conditions 
of severe hydrodynamic shear stress and reduced dissolved oxygen concentration.  These 
oxygen-depriving conditions alter the cell metabolism such that the main energy source 
occurs through glycolysis increasing the utilization of glucose and decreasing the 
utilization of glutamine (Mercille and Massie, 1994). 
The total apoptotic response correlated with the metabolic levels such as lactate 
buildup, glucose and glutamine limitation, sodium and potassium concentrations, 
osmolality, and the viable cell density, (see Appendix 3).  This is consistent with other 
findings that an effective inducer of apoptosis in cell culture processes has been found to 
be glutamine limitation followed by glucose limitation and ammonia and lactate toxicity 
(Singh et al., 1994; Mercille and Massie, 1994).  The total normalized protein yield was 
most affected by the viable cell density and the CPT induction, (see Appendix 4).  
Glucose levels and CPT inductions had the most significant effect on the specific 
productivity response, (see Appendix 5).  Figure 20 shows the response of specific 
productivity with an increase of viability.  As the viability increases, the specific 
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productivity decreases suggesting that apoptosis and cell death levels play a significant 
role in productivity of the culture most likely due to secondary necrosis. 
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Figure 20: Specific Productivity versus ViaCount Viability 
Figure 20 shows the response of specific productivity with the increase in cell viability.  
As the viability increases, the specific productivity decreases suggesting that apoptosis 
and cell death levels play a significant role in productivity of the culture. 
 
4. Conclusion & Future Experiments 
Results have shown that the Guava ViaCount method is more representative of 
actual viability levels in a cell culture process than the conventional trypan blue method.  
The ViaCount method was the simplest, most reproducible, and quickest of the three 
apoptosis assays.  It also provides a more accurate cell density measurement compared to 
the others.  The MultiCaspase assay results were slightly inconsistent since the assay is 
more sensitive and less robust than the other methods due to its complexity.  The assay is 
time consuming with long incubation times, multiple wash steps, and signal stability was 
an issue.  Because there is some overlap with the different stages of apoptosis, the results 
between the three Guava methods vary slightly.  To get a true representation of the 
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various apoptotic levels in the culture all three methods should be run.  For example, the 
MultiCaspase method reagent binds to many different caspases and earlier than the PS in 
Nexin, whereas the Nexin reagent only binds PS giving slightly lower levels of apoptosis.  
 The ViaCount method is recommended to determine viability and cell density 
more accurately over the trypan blue method, and it can be used for future optimization 
of the process.  The information from all three assays is useful depending on the stage of 
apoptosis that is being investigated.  The three apoptosis assays have been useful to 
determine the actual levels of viability in the process to establish which parameters have 
a significant affect on the viability, apoptotic levels, productivity and specific 
productivity of the model cell line.  This information is useful for process development to 
allow for optimization by inhibiting or regulating apoptotic levels, and consequently, the 
possibility to increase the viable cell density and productivity.   
Although apoptosis was not found to have a negative effect on total productivity 
in this particular cell culture process as hypothesized, the significant increase in the 
product yield and specific productivity are most likely due to release of product during 
secondary necrosis at the culmination of the apoptosis pathway.  Another possibility is 
that specific productivities have been shown to increase in nutrient-poor medium or 
apoptotic conditions because the cells are growth arrested and the cell’s resources can be 
used for protein production rather than cell proliferation.  The overall protein production 
could be reduced, however, due to the lower cell density (Mastrangelo and Betenbaugh, 
1998).  The decrease in productivity and lower apoptotic levels in the nutrient feed 
deprived run compared to the other two runs in Study 3 could be due to a slower 
metabolism from the nutrient starvation rather than inductions of the apoptosis cascade. 
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Although specific productivity has been shown to be elevated with increased 
apoptosis levels, this is most likely not a desired effect in an industrial cell culture 
process.  Cells that undergo apoptosis or necrosis release proteases and other components 
into the culture thereby decreasing cell proliferation and increasing the chance for 
product degradation.  In addition, the material released from secondary necrosis can 
cause production issues with downstream processing such as reducing the performance of 
tangential flow filtration processes.  Thus, higher product consistency and quality could 
be achieved by employing well-defined and reproducible culture conditions and by 
minimizing the release of intracellular proteases and glycosidases.  The effect on the 
quality of the product should be examined in future experiments as well as the level of 
cell lysis using lactate dehydrogenate as an internal marker for cell release.  Material 
harvested from the higher apoptotic cultures could also be purified with downstream 
processes to determine the effect of increased specific productivity due to apoptosis.  
Understanding how these levels correspond to productivity and product quality will allow 
for better control of cell culture processes in industrial scale processes. 
This study showed the correlation between the culture conditions and apoptosis 
during a mammalian cell culture process and its effects on the productivity using real-
time apoptotic assays for accurate cellular growth and death profiles.  This technology 
could be useful as a possible Process Analytical Technology (PAT) tool to monitor the 
manufacturing cell culture process real-time to detect cell culture quality issues early.  
PAT monitoring is becoming a hot topic in the industry and a desired technology by the 
regulatory agencies as a mode to ensure final product quality and build quality into the 
manufacturing process.   
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Another application could be as a process monitoring methodology for 
troubleshooting purposes.  It would be beneficial to determine which conditions the cell 
culture is sensitive to and to add additional process control to minimize apoptosis levels 
during process characterization.  Results from this study have shown that lower pH 
during cultivation decreases the viable cell density and increases apoptosis.  This is 
consistent with literature findings that acidic pH in the intracellular environment can 
increase caspase activity in the apoptosis pathway (Matsuyama et al., 2000 reviewed by 
Laken and Leonard, 2001).  Apoptosis was also significantly increased by glucose and 
glutamine limitation, lactate toxicity and other metabolite concentrations in the culture 
such as sodium and potassium.  Alternatively, lower dissolved oxygen levels increased 
the viable cell density and prolonged cell viability in the reactors thereby increasing the 
productivity.  Understanding what signals the apoptotic cascade and how to regulate it 
would provide a new opportunity to enhance process robustness, improve final 
performance including productivity, and, eventually, reduce production costs. 
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Appendix 1:  Statistical Analysis – Viable Cell Density Response 
Response: Live (cells/ml) 
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RSq=0.72 RMSE=1.05e6
 
Summary of Fit 
  
RSquare 0.716921
RSquare Adj 0.663843
Root Mean Square Error 1052291
Mean of Response 5608178
Observations (or Sum Wgts) 20
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio
Model 3 4.48698e13 1.4957e13 13.5071
Error 16 1.77171e13 1.1073e12 Prob > F
C. Total 19 6.25869e13 0.0001
Parameter Estimates 
Term   Estimate Std Error t Ratio Prob>|t|
Intercept  -37119190 16394561 -2.26 0.0378
pH  6589660.3 2399439 2.75 0.0143
O2 (mmHg)  -30437.64 8516.174 -3.57 0.0025
CPT addition[no]  1705045.3 394895.4 4.32 0.0005
Effect Tests 
Source Nparm DF Sum of Squares F Ratio Prob > F   
pH 1 1 8.35176e12 7.5423 0.0143  
O2 (mmHg) 1 1 1.4145e+13 12.7742 0.0025  
CPT addition 1 1 2.06433e13 18.6426 0.0005  
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CPT addition Leverage Plot 
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Least Squares Means Table 
Level Least Sq Mean Std Error Mean
no 5949187.3 248200.53 5958359
yes 2539096.6 748745.08 2456547
 
Response Live (cells/ml) including Studies 2 and 4 
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RSq=0.93 RMSE=578724
 
Summary of Fit 
  
RSquare 0.930679
RSquare Adj 0.901351
Root Mean Square Error 578723.6
Mean of Response 6761387
Observations (or Sum Wgts) 38
 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio
Model 11 1.1691e+14 1.0628e13 31.7334
Error 26 8.70795e12 3.3492e11 Prob > F
C. Total 37 1.25618e14 <.0001
Parameter Estimates 
Term   Std Error t Ratio Prob>|t|
Intercept  41468979 4.34 0.0002
pH  6752942 -3.34 0.0026
CO2 (mmHg)  10123.43 -0.30 0.7632
O2 (mmHg)  6462.66 0.74 0.4650
Gluc (g/l)  2687433 0.35 0.7290
Lac (g/l)  2160804 0.49 0.6289
Gln (mM)  625092 -2.17 0.0392
Glu (mM)  1381584 -0.94 0.3573
NH4+ (mM)  690184.9 -2.10 0.0453
Na+ (mM)  314573.4 1.53 0.1388
K+ (mM)  1063752 0.87 0.3940
Osm (mOsm/kg)  177829.3 -1.21 0.2359
Page 54 of 71 
Effect Tests 
Source Nparm DF Sum of Squares F Ratio Prob > F   
pH 1 1 3.73023e12 11.1377 0.0026  
CO2 (mmHg) 1 1 3.10503e10 0.0927 0.7632  
O2 (mmHg) 1 1 1.84199e11 0.5500 0.4650  
Gluc (g/l) 1 1 4.10792e10 0.1227 0.7290  
Lac (g/l) 1 1 8.01219e10 0.2392 0.6289  
Gln (mM) 1 1 1.57941e12 4.7158 0.0392  
Glu (mM) 1 1 2.94212e11 0.8785 0.3573  
NH4+ (mM) 1 1 1.48045e12 4.4203 0.0453  
Na+ (mM) 1 1 7.81221e11 2.3326 0.1388  
K+ (mM) 1 1 2.51662e11 0.7514 0.3940  
Osm (mOsm/kg) 1 1 4.93045e11 1.4721 0.2359  
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Appendix 2:  Statistical Analysis – Total Viability Response 
 
Response: ViaCount Live (%) 
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Summary of Fit 
  
RSquare 0.951543
RSquare Adj 0.925295
Root Mean Square Error 0.82483
Mean of Response 90.85505
Observations (or Sum Wgts) 38
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio
Model 13 320.63322 24.6641 36.2523
Error 24 16.32829 0.6803 Prob > F
C. Total 37 336.96150 <.0001
Parameter Estimates 
Term   Std Error t Ratio Prob>|t|
Intercept  77.63687 0.70 0.4914
pH  11.50668 0.90 0.3759
CO2 (mmHg)  0.015966 -2.32 0.0289
O2 (mmHg)  0.010177 -1.35 0.1904
Gluc (g/l)  3.993405 -3.53 0.0017
Lac (g/l)  3.187788 -1.79 0.0856
Gln (mM)  0.972432 1.85 0.0768
Glu (mM)  2.142376 -2.21 0.0365
NH4+ (mM)  1.075727 1.88 0.0726
Na+ (mM)  0.470164 -0.50 0.6223
K+ (mM)  1.60696 -0.66 0.5144
Osm (mOsm/kg)  0.262061 0.39 0.7007
Live (cells/ml)  3.674e-7 0.25 0.8072
CPT Induction[n]  0.671531 8.16 <.0001
Effect Tests 
Source Nparm DF Sum of Squares F Ratio Prob > F   
pH 1 1 0.553918 0.8142 0.3759  
CO2 (mmHg) 1 1 3.674840 5.4014 0.0289  
O2 (mmHg) 1 1 1.235309 1.8157 0.1904  
Gluc (g/l) 1 1 8.466409 12.4443 0.0017  
Lac (g/l) 1 1 2.186981 3.2145 0.0856  
Gln (mM) 1 1 2.326500 3.4196 0.0768  
Glu (mM) 1 1 3.336935 4.9048 0.0365  
NH4+ (mM) 1 1 2.398443 3.5253 0.0726  
Na+ (mM) 1 1 0.169464 0.2491 0.6223  
K+ (mM) 1 1 0.297940 0.4379 0.5144  
Osm (mOsm/kg) 1 1 0.102931 0.1513 0.7007  
Live (cells/ml) 1 1 0.041445 0.0609 0.8072  
CPT Induction 1 1 45.312072 66.6016 <.0001  
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PH Leverage Plot    CO2 (mmHg) Leverage Plot 
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Least Squares Means Table 
Level Least Sq Mean   Std Error Mean
n 91.431934  0.1513293 91.4871
y 80.471227  1.2793914 79.4786
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Appendix 3:  Statistical Analysis – Total Apoptotic Response 
 
Response: Total Apoptotic (%) 
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Summary of Fit 
  
RSquare 0.981197
RSquare Adj 0.940456
Root Mean Square Error 1.914832
Mean of Response 25.38245
Observations (or Sum Wgts) 20
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio
Model 13 1147.9694 88.3053 24.0838
Error 6 21.9995 3.6666 Prob > F
C. Total 19 1169.9689 0.0004
Parameter Estimates 
Term   Std Error t Ratio Prob>|t|
Intercept  393.3158 3.28 0.0167
pH  48.31232 -2.02 0.0904
CO2 (mmHg)  0.05416 2.55 0.0437
O2 (mmHg)  0.040102 -0.36 0.7291
Glucose(g/l)  20.77028 4.43 0.0044
Lactate (g/l)  30.8474 4.21 0.0056
Glutamine (mM)  4.672703 -3.74 0.0096
Glutamate (mM)  15.46097 0.95 0.3773
Ammonium(mM)  5.764247 0.81 0.4498
Na+ (mM)  5.525022 3.73 0.0097
K+ (mM)  9.528369 3.89 0.0081
Osmolality (mOsm/kg)  2.850858 -3.89 0.0081
Cells x Time (e6cell-day)  0.54483 1.60 0.1597
Live (cells/ml)  0.000002 -4.64 0.0036
Effect Tests 
Source Nparm DF Sum of Squares F Ratio Prob > F   
pH 1 1 14.904237 4.0649 0.0904  
CO2 (mmHg) 1 1 23.785720 6.4872 0.0437  
O2 (mmHg) 1 1 0.482775 0.1317 0.7291  
Glucose (g/l) 1 1 71.902072 19.6101 0.0044  
Lacate (g/l) 1 1 64.899220 17.7002 0.0056  
Glutamine (mM) 1 1 51.253336 13.9785 0.0096  
Glutamate (mM) 1 1 3.331756 0.9087 0.3773  
Ammonium (mM) 1 1 2.395305 0.6533 0.4498  
Na+ (mM) 1 1 51.040204 13.9204 0.0097  
K+ (mM) 1 1 55.515723 15.1410 0.0081  
Osmolality (mOsm/kg) 1 1 55.359621 15.0984 0.0081  
Cells x Time (e6cell-day) 1 1 9.439182 2.5744 0.1597  
Live (cells/ml) 1 1 78.792605 21.4894 0.0036  
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Appendix 4:  Statistical Analysis – Total Protein Response 
 
Response Normalized Total Protein (mg) 
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Summary of Fit 
  
RSquare 0.918137
RSquare Adj 0.868307
Root Mean Square Error 85.3803
Mean of Response 1597.377
Observations (or Sum Wgts) 38
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio
Model 14 1880446.2 134318 18.4254
Error 23 167665.3 7290 Prob > F
C. Total 37 2048111.5 <.0001
Parameter Estimates 
Term   Std Error t Ratio Prob>|t|
Intercept  8339.06 1.02 0.3186
pH  1236.079 -0.83 0.4135
CO2 (mmHg)  2.043573 0.44 0.6666
O2 (mmHg)  1.12642 1.33 0.1967
Gluc (g/l)  480.8488 -0.75 0.4601
Lac (g/l)  382.7342 0.24 0.8114
Gln (mM)  107.2701 1.73 0.0975
Glu (mM)  236.0006 -1.21 0.2386
NH4+ (mM)  118.1159 1.03 0.3115
Na+ (mM)  49.6342 1.17 0.2556
K+ (mM)  178.5916 -0.40 0.6946
Osm (mOsm/kg)  27.94619 -0.78 0.4423
Live (cells/ml)  0.000038 4.20 0.0003
CPT Induction[n]  95.43862 -4.45 0.0002
Total Apoptotic (%)  7.323472 0.92 0.3683
Effect Tests 
Source Nparm DF Sum of Squares F Ratio Prob > F   
pH 1 1 5055.49 0.6935 0.4135  
CO2 (mmHg) 1 1 1388.11 0.1904 0.6666  
O2 (mmHg) 1 1 12884.27 1.7674 0.1967  
Gluc (g/l) 1 1 4114.58 0.5644 0.4601  
Lac (g/l) 1 1 424.82 0.0583 0.8114  
Gln (mM) 1 1 21757.03 2.9846 0.0975  
Glu (mM) 1 1 10673.08 1.4641 0.2386  
NH4+ (mM) 1 1 7806.06 1.0708 0.3115  
Na+ (mM) 1 1 9911.36 1.3596 0.2556  
K+ (mM) 1 1 1152.39 0.1581 0.6946  
Osm (mOsm/kg) 1 1 4456.32 0.6113 0.4423  
Live (cells/ml) 1 1 128527.21 17.6311 0.0003  
CPT Induction 1 1 144623.39 19.8392 0.0002  
Total Apoptotic (%) 1 1 6139.17 0.8422 0.3683  
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Residual by Predicted Plot   pH Leverage Plot 
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CPT Induction Leverage Plot 
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Least Squares Means Table 
Level Least Sq Mean   Std Error Mean
n 1552.6300  17.11030 1592.05
y 2402.8196  181.36073 1693.33
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Appendix 5: Statistical Analysis - Specific Productivity Response 
Response Specific Productivity ug/cell  
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Summary of Fit 
  
RSquare 0.90961
RSquare Adj 0.885507
Root Mean Square Error 0.08564
Mean of Response 0.260701
Observations (or Sum Wgts) 20
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio
Model 4 1.1070904 0.276773 37.7371
Error 15 0.1100135 0.007334 Prob > F
C. Total 19 1.2171039 <.0001
Parameter Estimates 
Term   Std Error t Ratio Prob>|t|
Intercept  1.762433 0.15 0.8810
pH  0.244741 0.06 0.9541
CO2 (mmHg)  0.001105 -4.93 0.0002
Total Apoptotic (%)  0.003315 7.01 <.0001
O2 (mmHg)  0.000712 -2.90 0.0111
Effect Tests 
Source Nparm DF Sum of Squares F Ratio Prob > F   
pH 1 1 0.00002507 0.0034 0.9541  
CO2 (mmHg) 1 1 0.17835510 24.3182 0.0002  
Total Apoptotic (%) 1 1 0.36037538 49.1361 <.0001  
O2 (mmHg) 1 1 0.06151744 8.3877 0.0111  
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pH Leverage Plot    CO2 (mmHg) Leverage Plot 
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Response: Specific Productivity ug/cell with both Studies 2 and 4 
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Summary of Fit 
  
RSquare 0.980606
RSquare Adj 0.968801
Root Mean Square Error 0.03298
Mean of Response 0.228901
Observations (or Sum Wgts) 38
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Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio
Model 14 1.2648873 0.090349 83.0671
Error 23 0.0250163 0.001088 Prob > F
C. Total 37 1.2899036 <.0001
Parameter Estimates 
Term Std Error t Ratio Prob>|t|
Intercept 3.111373 0.69 0.5001
pH 0.465864 -0.85 0.4030
CO2 (mmHg) 0.000761 1.51 0.1450
O2 (mmHg) 0.000414 1.35 0.1899
Gluc (g/l) 0.175868 3.73 0.0011
Lac (g/l) 0.131577 2.12 0.0450
Gln (mM) 0.048734 -2.07 0.0501
Glu (mM) 0.095652 0.65 0.5228
NH4+ (mM) 0.043782 -1.41 0.1706
Na+ (mM) 0.018867 1.51 0.1439
K+ (mM) 0.06534 1.60 0.1242
Osm (mOsm/kg) 0.010489 -1.24 0.2286
Live (cells/ml) 1.543e-8 0.02 0.9857
Mid Apoptotic (cells/ml) 2.136e-7 -2.14 0.0435
CPT Induction[n] 0.028605 -13.76 <.0001
Effect Tests 
Source Nparm DF Sum of Squares F Ratio Prob > F   
pH 1 1 0.00078956 0.7259 0.4030  
CO2 (mmHg) 1 1 0.00247605 2.2765 0.1450  
O2 (mmHg) 1 1 0.00198489 1.8249 0.1899  
Gluc (g/l) 1 1 0.01515846 13.9367 0.0011  
Lac (g/l) 1 1 0.00488729 4.4934 0.0450  
Gln (mM) 1 1 0.00464846 4.2738 0.0501  
Glu (mM) 1 1 0.00045799 0.4211 0.5228  
NH4+ (mM) 1 1 0.00217615 2.0008 0.1706  
Na+ (mM) 1 1 0.00248989 2.2892 0.1439  
K+ (mM) 1 1 0.00277021 2.5469 0.1242  
Osm (mOsm/kg) 1 1 0.00166411 1.5300 0.2286  
Live (cells/ml) 1 1 0.00000036 0.0003 0.9857  
Mid Apoptotic (cells/ml) 1 1 0.00496354 4.5635 0.0435  
CPT Induction 1 1 0.20594530 189.3464 <.0001  
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CO2 (mmHg) Leverage Plot   O2 (mmHg) Leverage Plot 
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CPT Induction Leverage Plot 
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Least Squares Means Table 
Level Least Sq Mean   Std Error Mean
n 0.18746828  0.00613913 0.186946
y 0.97468680  0.05446172 0.984081
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